We're On a Mission to Help Reduce the Incidence of Late Stage Cancer Through Early InterventionsToday most cancer research is focused on the "Moonshot" a cure for cancer. But at StageZero Life Sciences we believe in "groundshots" too, by doing whatever we can to help improve outcomes through cancer prevention, earlier cancer detection and adjunctive cancer therapies.
(TSX:SZLS) (OTCQB:SZLSF) |
|
|
Learn More About our ARISTOTLE test by watching the video below.
|
Early Cancer DetectionStageZero Life Sciences is dedicated to finding cancer in the earliest stages when it is most curable. Our next-generation test, ARISTOTLE®, can simultaneously screen for multiple cancers from a single blood sample. ARISTOTLE has been built on the company's mRNA Sentinel Principle Technology® Platform, which has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
Cancer Prevention & Adjunctive Cancer Therapies
In addition to early cancer detection, our Care Oncology clinicians apply their expertise in metabolic oncology to oversee two critical programs that support our mission: Investor PresentationStageZero Life Sciences Q3 2022 Earnings Call / Presentation
In The NewsStageZero Life Sciences was recently featured on BNN Bloomberg.
Press Releases |
|
Investor Relations Contacts
James R. Howard-Tripp Chairman and CEO jht@stagezerols.com Rebecca Greco Investor Relations rgreco@stagezerols.com 1-855-420-7140 ext 1838 Corporate Headquarters 30-70 East Beaver Creek Road Richmond Hill, ON L4B 3B2 contact@stagezerols.com |
Stay In Touch! Subscribe to Our Investor Updates |
